| scholarly article | Q13442814 |
| P2093 | author name string | R Vanholder | |
| W Van Biesen | |||
| S Van Laecke | |||
| P2860 | cites work | Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies | Q26828820 |
| A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation | Q26850196 | ||
| Hypomagnesaemia, the kidney and the vessels | Q26853709 | ||
| The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study | Q31138001 | ||
| Muscle sympathetic nerve activity is related to a surrogate marker of endothelial function in healthy individuals | Q33533352 | ||
| The relationship between hemoglobin levels and endothelial functions in diabetes mellitus | Q33571310 | ||
| Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women | Q33602201 | ||
| Avosentan for overt diabetic nephropathy | Q33702404 | ||
| Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 | ||
| A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas | Q34277465 | ||
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease | Q34383685 | ||
| Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl | Q34423200 | ||
| Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study | Q34567058 | ||
| Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited | Q35138063 | ||
| Bardoxolone methyl decreases megalin and activates nrf2 in the kidney | Q36280389 | ||
| Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. | Q36410781 | ||
| Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease | Q36788430 | ||
| Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease | Q37073587 | ||
| Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes | Q37251105 | ||
| Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study | Q37289665 | ||
| Endothelial cells and magnesium: implications in atherosclerosis | Q37976136 | ||
| Endothelin antagonists in hypertension and kidney disease | Q38052428 | ||
| Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients | Q41955256 | ||
| Magnesium orotate in severe congestive heart failure (MACH). | Q43416048 | ||
| Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects | Q43475358 | ||
| Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study | Q43598066 | ||
| Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease | Q43767561 | ||
| Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study | Q44433022 | ||
| Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease | Q44806693 | ||
| Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. | Q45926436 | ||
| Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies | Q47841392 | ||
| Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. | Q51496620 | ||
| Bardoxolone Methyl, Chronic Kidney Disease, and Type 2 Diabetes | Q56775182 | ||
| Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis | Q58362776 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 9-14 | |
| P577 | publication date | 2014-08-04 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | The paradox of bardoxolone methyl: a call for every witness on the stand? | |
| P478 | volume | 17 |
| Q51723059 | C-reactive Protein: Repeated Measurements will Improve Dialysis Patient Care. |
| Q55476982 | Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). |
| Q38687425 | Diabetic cardiomyopathy: role of the E3 ubiquitin ligase |
| Q39327680 | Diabetic nephropathy: Time to withhold development and progression - A review |
| Q38922337 | Inhibitory Effects of Polydatin on Lipopolysaccharide-Stimulated RAW 264.7 Cells |
| Q51092133 | Insulin Inhibits Nrf2 Gene Expression via Heterogeneous Nuclear Ribonucleoprotein F/K in Diabetic Mice. |
| Q26739475 | New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease |
| Q47350229 | Nrf2 at the Heart of Oxidative Stress and Cardiac Protection |
| Q55066483 | The targeted anti-oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue. |
Search more.